Carregant...
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats
Chronic Levodopa (L-DOPA), the gold standard therapy for Parkinson’s disease (PD), causes disabling motor complications (dyskinesias) that are associated with changes in the activity of striatal protein kinase A (PKA) and cAMP-regulated phosphoprotein of 32 KDa (DARPP-32). In this study, we showed t...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3273613/ https://ncbi.nlm.nih.gov/pubmed/22192465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neures.2011.12.006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|